Chitosan/Orthobiologics Biomaterials for Regenerative Medicine

用于再生医学的壳聚糖/Orthobiologics 生物材料

• 批准号: 577048-2022
• 负责人: Lavertu, MarcM
• 金额: $ 15.81万
• 依托单位: École Polytechnique de Montréal
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=753704
• 关键词: Chitosan; Orthobiologics; Biomaterials; Regenerative; Medicine

The main goal of the project is to design and create biomaterials to improve treatment of musculoskeletaldisorders, which affect 1.7 billion people globally. The Ortho-R technology, invented at PolytechniqueMontreal, was acquired in 2015 by Ortho Regenerative Technologies Inc (Ortho RTI), and the 2 entities havesince collaborated to pursue its development. A clinical study for the repair of torn tendons has begun in 2022in the United States. R&D work is required to further advance the Ortho-R technology. The company alsowishes to explore new indications for Ortho-R and develop new biomaterials for regenerative medicine. Thetargeted indications are the repair/regeneration of soft tissues (tendon, meniscus, cartilage, ligament), in order to address major medical needs that are largely unmet. The objectives of the project are A) to optimize the manufacturing processes of Ortho-R, B) to elucidate the modes of action and to characterize the structural/mechanical properties of the repair tissues obtained with Ortho-R treatment, C) to assess the potential of Ortho-R for the repair of ligaments and D) to develop new biomaterials with improved properties. This research project will generate new technologies and new intellectual property in the field of regenerative medicine.This project will allow Ortho RTI to continue the development of Ortho-R and to develop new biomaterialsto expand its product portfolio. It will also generate new standardized mechanical tests, in addition to trainingfuture employees of the company Biomomentum. Eventually, new know-how in biomaterial production andanalytical methods will lead to job creation at KABS Laboratories and CERASP. Around 20 highlyspecialized/paid jobs in the promising field of life sciences will be created and highly qualified personnel (>35)will be trained in a professional working/training environment. This large-scale project will make it possible toaddress major medical needs that are largely unmet and will strengthen Canada's leading position in lifesciences while contributing to the country's economic growth.

该项目的主要目标是设计和制造生物材料，以改善肌肉骨骼疾病的治疗，该疾病影响着全球 17 亿人。 Ortho-R 技术由蒙特利尔理工学院发明，于 2015 年被 Ortho Rogenic Technologies Inc (Ortho RTI) 收购，此后两家公司一直合作开发该技术。一项修复撕裂肌腱的临床研究已于 2022 年在美国开始。需要开展研发工作来进一步推进 Ortho-R 技术。该公司还希望探索 Ortho-R 的新适应症，并开发用于再生医学的新生物材料。目标适应症是软组织（肌腱、半月板、软骨、韧带）的修复/再生，以解决很大程度上未得到满足的主要医疗需求。该项目的目标是 A) 优化 Ortho-R 的制造工艺，B) 阐明作用模式并表征通过 Ortho-R 治疗获得的修复组织的结构/机械特性，C) 评估 Ortho-R 修复韧带的潜力，D) 开发具有改进特性的新型生物材料。该研究项目将在再生医学领域产生新技术和新知识产权。该项目将使Ortho RTI能够继续开发Ortho-R并开发新的生物材料以扩大其产品组合。除了培训 Biomomentum 公司的未来员工外，它还将生成新的标准化机械测试。最终，生物材料生产和分析方法方面的新专业知识将为 KABS 实验室和 CERASP 创造就业机会。在前景广阔的生命科学领域将创造约 20 个高度专业化/高薪的工作岗位，高素质人才（>35 人）将在专业的工作/培训环境中接受培训。这一大型项目将有可能解决很大程度上未得到满足的主要医疗需求，并将加强加拿大在生命科学领域的领先地位，同时为国家经济增长做出贡献。